The Movement Disorder Journal and News

TogetherForSharon®: Fighting Parkinson’s by Transforming Grief into Advocacy for Parkinson’s Awareness

29 min · 4 de jun de 2026
Portada del episodio TogetherForSharon®: Fighting Parkinson’s by Transforming Grief into Advocacy for Parkinson’s Awareness

Descripción

After losing his mother, Sharon, to Parkinson’s disease, Dr. George Ackerman transformed personal tragedy into a nationwide advocacy movement. Through TogetherForSharon, he is working to raise awareness, educate communities, support research, and give a voice to families affected by Parkinson’s. This is a story about resilience, purpose, and how one family's loss became a source of hope for millions of others.

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de The Movement Disorder Journal and News!

Prueba gratis

Empieza 7 días de prueba

$99 / mes después de la prueba. · Cancela cuando quieras.

  • Podcasts solo en Podimo
  • 20 horas de audiolibros al mes
  • Podcast gratuitos

Todos los episodios

6 episodios

episode Neuralight's Eye-Movement Software and the MDS-UPDRS artwork

Neuralight's Eye-Movement Software and the MDS-UPDRS

In this episode, we sit down with Dr. Eitan Raveh, VP of Clinical Partnerships at NeuraLight, to explore a technology that could reshape how Parkinson's disease is measured and tracked in clinical trials. For nearly four decades, the MDS-UPDRS has been the gold standard for evaluating Parkinson's progression, but a new study suggests that a simple eye-tracking test, administered on a tablet in about ten minutes, may be more sensitive at detecting disease progression than the scale neurologists have relied on for generations. Dr. Raveh walks us through NeuraLight's landmark longitudinal study, what the Amplitude of Saccadic Hypometria actually measures, and why two of the scientists who helped build the MDS-UPDRS are now co-authors on a paper showing it may have met its match. If you follow Parkinson's research, drug development, or the future of digital biomarkers in neurology, this is a conversation you won't want to miss.

18 de jun de 202632 min